Skip to main content
Premium Trial:

Request an Annual Quote

FDA, EMEA Release Joint Pharmacogenomics Data-Submission Guidance

NEW YORK, June 1 (GenomeWeb News) - US and European drug regulators today said they have agreed to a joint procedure that drug makers can follow to voluntarily submit pharmacogenomic data to both agencies.

 

The document, which can be found here, could benefit pharmaceutical companies interested in simultaneously selling products in Europe and the US that have pharmacogenomic components.

 

Specifically, the European Medicines Agency and the US Food and Drug Administration today released a set of "guiding principles" describing how they will process drug makers' requests to jointly meet with both agencies about voluntary genomic data submission.

 

The guiding principles have a list of definitions agreed to by the agencies, and a flowchart describing how voluntary submissions would be procssed. The FDA's Interdisciplinary Pharmacogenomic Review Group and the EMEA's Pharmacogenetics Working Party will review the data submission packages.

 

The FDA and the EMEA have issued industry guidance on pharmacogenomic data submissions and briefing meetings in the past. While researchers are not required to submit pharmacogenomic data to health authorities in most cases, voluntary submissions are encouraged to help regulators become familiar with issues arising in drug development.

 

The FDA published guidelines on voluntary submissions in 2004. The FDA and EMEA informally met at the time to help the agencies synchronize their pharmacogenomic goals and strategies. The most recent guidance for voluntary submissions on the FDA web site is dated March 2005.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.